Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 18, 2020Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer
-
Jan 15, 2020Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
-
Dec 9, 2019- Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation
-
Nov 20, 2019- Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort
-
Nov 15, 2019- Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019
-
Nov 13, 2019- Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
-
Nov 5, 2019Dr. Paul Barsanti joins as Vice President, Head of Drug Discovery
-
Oct 31, 2019- FDA feedback from End‑of‑Phase 1 meeting indicates IDEAYA's proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)